 |
|
Impact of Varicella Vaccination on Health Care Utilization
Fangjun Zhou, PhD, MS;
Rafael Harpaz, MD, MPH;
Aisha O. Jumaan, PhD, MPH;
Carla A. Winston, PhD, MA;
Abigail Shefer, MD
JAMA. 2005;294:797-802.
Context Since varicella vaccine was first recommended for routine immunization in the United States in 1995, the incidence of disease has dropped substantially. However, national surveillance data are incomplete, and comprehensive data regarding outpatient as well as hospital utilization have not been reported.
Objective To examine the impact of the varicella vaccination program on medical visits and associated expenditures.
Design, Setting, and Patients Retrospective population-based study examining the trends in varicella health care utilization, based on data from the MarketScan databases, which include enrollees (children and adults) of more than 100 health insurance plans of approximately 40 large US employers, from 1994 to 2002.
Main Outcome Measures Trends in rates of varicella-related hospitalizations and ambulatory visits and direct medical expenditures for hospitalizations and ambulatory visits, analyzed using 1994 and 1995 as the prevaccination baseline.
Results From the prevaccination period to 2002, hospitalizations due to varicella declined by 88% (from 2.3 to 0.3 per 100 000 population) and ambulatory visits declined by 59% (from 215 to 89 per 100 000 population). Hospitalizations and ambulatory visits declined in all age groups, with the greatest declines among infants younger than 1 year. Total estimated direct medical expenditures for varicella hospitalizations and ambulatory visits declined by 74%, from an average of $84.9 million in 1994 and 1995 to $22.1 million in 2002.
Conclusion Since the introduction of the varicella vaccination program, varicella hospitalizations, ambulatory visits, and their associated expenditures have declined dramatically among all age groups in the United States.
Author Affiliations: National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Ga. Dr Jumaan is now with the Agency for Toxic Substances and Disease Registry, Atlanta, Ga.
RELATED ARTICLES
Varicella Vaccine, Cost-effectiveness Analyses, and Vaccination Policy
Matthew M. Davis
JAMA. 2005;294(7):845-846.
EXTRACT
| FULL TEXT
Chickenpox
Sharon Parmet, Cassio Lynm, and Richard M. Glass
JAMA. 2005;294(7):866.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Complete DNA Sequences of Two Oka Strain Varicella-Zoster Virus Genomes
Tillieux et al.
J. Virol. 2008;82:11023-11044.
ABSTRACT
| FULL TEXT
Varicella Prevention in the United States: A Review of Successes and Challenges
Marin et al.
Pediatrics 2008;122:e744-e751.
ABSTRACT
| FULL TEXT
Childhood immunisation against varicella zoster virus
Farlow
BMJ 2008;337:a1164-a1164.
FULL TEXT
Infectious Disease Hospitalizations Among Infants in the United States
Yorita et al.
Pediatrics 2008;121:244-252.
ABSTRACT
| FULL TEXT
Delivering New Vaccines to Adolescents: The Role of School-Entry Laws
Horlick et al.
Pediatrics 2008;121:S79-S84.
ABSTRACT
| FULL TEXT
Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States
Roush et al.
JAMA 2007;298:2155-2163.
ABSTRACT
| FULL TEXT
Severe Varicella Caused by Varicella-Vaccine Strain in a Child With Significant T-Cell Dysfunction
Jean-Philippe et al.
Pediatrics 2007;120:e1345-e1349.
ABSTRACT
| FULL TEXT
Prevention of Varicella: Recommendations for Use of Varicella Vaccines in Children, Including a Recommendation for a Routine 2-Dose Varicella Immunization Schedule
Committee on Infectious Diseases
Pediatrics 2007;120:221-231.
ABSTRACT
| FULL TEXT
Varicella Vaccine
Gershon et al.
NEJM 2007;356:2648-2649.
FULL TEXT
Loss of Vaccine-Induced Immunity to Varicella over Time
Chaves et al.
NEJM 2007;356:1121-1129.
ABSTRACT
| FULL TEXT
Physician Attitudes Regarding Breakthrough Varicella Disease and a Potential Second Dose of Varicella Vaccine
Davis et al.
Pediatrics 2007;119:258-264.
ABSTRACT
| FULL TEXT
A balancing act
Wood et al.
EDUCATION AND PRACTICE 2006;91:ep68-ep74.
FULL TEXT
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger and Robertus
ANN INTERN MED 2006;145:317-325.
ABSTRACT
| FULL TEXT
Will Coverage for Child and Adolescent Immunizations Be Mandated for Insurance Plans in 2006? Lessons Learned From the Newborns' and Mothers' Health Protection Act of 1996
Mmeje and Davis
Pediatrics 2006;118:388-392.
FULL TEXT
A Decade of Varicella Vaccine Has Made a Difference
JWatch Emergency Med. 2005;2005:3-3.
FULL TEXT
Effect of the Varicella Vaccine
Journal Watch Dermatology 2005;2005:11-11.
FULL TEXT
Vaccine Has Markedly Reduced Varicella-Associated Healthcare Utilization
JWatch Infect. Diseases 2005;2005:4-4.
FULL TEXT
Effect of the Varicella Vaccine
JWatch General 2005;2005:6-6.
FULL TEXT
What's new in the other general journals
Martyn
BMJ 2005;331:537-538.
FULL TEXT
Varicella Vaccine, Cost-effectiveness Analyses, and Vaccination Policy
Davis
JAMA 2005;294:845-846.
FULL TEXT
|
